The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial.

Yi L, Maier AB, Tao R, Lin Z, Vaidya A, Pendse S, Thasma S, Andhalkar N, Avhad G, Kumbhar V

GeroScience8 Dec 2022Cited by 139 (Europe PMC)

PMID36482258PMCIDPMC9735188DOI10.1007/s11357-022-00705-1PepBankPUB-36482258

Summary

In animal studies, β-nicotinamide mononucleotide (NMN) supplementation increases nicotinamide adenine dinucleotide (NAD) concentrations and improves healthspan and lifespan with great safety. However, it is unclear if these effects can be transferred to humans. This randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial included 80 middle-aged healthy adults being randomized for a 60-day clinical trial with once daily oral dosing of placebo, 300 mg, 600 mg, or 900 mg NMN. The primary objective was to evaluate blood NAD concentration with dose-dependent regimens. The secondary objectives were to assess the safety and tolerability of NMN supplementation, next to the evaluation of clinical efficacy by measuring physical performance (six-minute walking test), blood biological age (Aging.Ai 3.0 calculator), Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), and subjective general health assessment [36-Item Short Form Survey Instrument (SF-36)]. Statistical analysis was performed using the Per Protocol analysis with significant level set at p = 0.05. All 80 participants completed the trial without trial protocol violation. Blood NAD concentrations were statistically significantly increased among all NMN-treated groups at day 30 and day 60 when compared to both placebo and baseline (all p ≤ 0.001). Blood NAD concentrations were highest in the groups taking 600 mg and 900 mg NMN. No safety issues, based on monitoring adverse events (AEs), laboratory and clinical measures, were found, and NMN supplementation was well tolerated. Walking distance increase during the six-minute walking test was statistically significantly higher in the 300 mg, 600 mg, and 900 mg groups compared to placebo at both days 30 and 60 (all p < 0.01), with longest walking distances measured in the 600 mg and 900 mg groups. The blood biological age increased significantly in the placebo group and stayed unchanged in all NMN-treated groups at day 60, which resulted in a significant difference between the treated groups and placebo (all p < 0.05). The HOMA-IR showed no statistically significant differences for all NMN-treated groups as compared to placebo at day 60. The change of SF-36 scores at day 30 and day 60 indicated statistically significantly better health of all three treated groups when compared to the placebo group (p < 0.05), except for the SF-36 score change in the 300 mg group at day 30. NMN supplementation increases blood NAD concentrations and is safe and well tolerated with oral dosing up to 900 mg NMN daily. Clinical efficacy expressed by blood NAD concentration and physical performance reaches highest at a dose of 600 mg daily oral intake. This trial was registered with ClinicalTrials.gov, NCT04823260, and Clinical Trial Registry - India, CTRI/2021/03/032421.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In healthy middle-aged adults, NMN at 300, 600 and 900 mg daily increased blood NAD versus placebo and baseline at days 30 and 60, with the highest levels at 600 mg and 900 mg.
In plain wordsIn healthy middle-aged adults, NMN raised blood NAD more than placebo at days 30 and 60, and most at 600 mg and 900 mg.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
IncreaseBlood NAD at days 30 and 60
Study
n = 80
Comparator
placebo
Analysis
Primary
Outcome group
Pharmacokinetics · Metabolic and weight
Studied dose
300, 600, or 900 mg daily · oral · 60 daysAs given in this study (human).
Source sentences
Summary
Blood NAD concentrations were statistically significantly increased among all NMN-treated groups at day 30 and day 60 when compared to both placebo and baseline (all p ≤ 0.001). Blood NAD concentrations were highest in the groups taking 600 mg and 900 mg NMN.
2 context sentences(design, population, supporting numbers)
Summary · context
This randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial included 80 middle-aged healthy adults being randomized for a 60-day clinical trial with once daily oral dosing of placebo, 300 mg, 600 mg, or 900 mg NMN.
Summary · context
The primary objective was to evaluate blood NAD concentration with dose-dependent regimens.
Show in the study text Report a problemFND-3648225801
02HumanRandomized controlled trialSafety outcome
In healthy middle-aged adults, NMN was well tolerated with no safety issues on adverse-event, laboratory, and clinical monitoring.
In plain wordsIn healthy middle-aged adults, NMN was well tolerated, with no safety issues found through adverse-event, laboratory, or clinical monitoring.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
Direction not reportedSafety and tolerability
Study
n = 80
Analysis
Secondary
Outcome group
Adverse events · Whole body
Studied dose
300 mg, 600 mg, or 900 mg daily · oral · 60 daysAs given in this study (human).
Source sentences
Summary
No safety issues, based on monitoring adverse events (AEs), laboratory and clinical measures, were found, and NMN supplementation was well tolerated.
3 context sentences(design, population, supporting numbers)
Summary · context
This randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial included 80 middle-aged healthy adults being randomized for a 60-day clinical trial with once daily oral dosing of placebo, 300 mg, 600 mg, or 900 mg NMN.
Summary · context
The secondary objectives were to assess the safety and tolerability of NMN supplementation, next to the evaluation of clinical efficacy by measuring physical performance (six-minute walking test), blood biological age (Aging.Ai 3.0 calculator), Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), and subjective general health assessment [36-Item Short Form Survey Instrument (SF-36)].
Summary · context
All 80 participants completed the trial without trial protocol violation.
Show in the study text Report a problemFND-3648225805
03HumanRandomized controlled trialEfficacy outcome
In healthy middle-aged adults, NMN at 300, 600 and 900 mg daily increased six-minute walking distance more than placebo at days 30 and 60, with the longest distances at 600 mg and 900 mg.
In plain wordsIn healthy middle-aged adults, NMN increased walking distance more than placebo at days 30 and 60, most at 600 mg and 900 mg.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
IncreaseSix-minute walking distance at days 30 and 60
Study
n = 80
Comparator
placebo
Analysis
Secondary
Outcome group
Exercise and physical function · Musculoskeletal
Studied dose
300, 600, or 900 mg daily · oral · 60 daysAs given in this study (human).
Source sentences
Summary
Walking distance increase during the six-minute walking test was statistically significantly higher in the 300 mg, 600 mg, and 900 mg groups compared to placebo at both days 30 and 60 (all p < 0.01), with longest walking distances measured in the 600 mg and 900 mg groups.
2 context sentences(design, population, supporting numbers)
Summary · context
This randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial included 80 middle-aged healthy adults being randomized for a 60-day clinical trial with once daily oral dosing of placebo, 300 mg, 600 mg, or 900 mg NMN.
Summary · context
The secondary objectives were to assess the safety and tolerability of NMN supplementation, next to the evaluation of clinical efficacy by measuring physical performance (six-minute walking test), blood biological age (Aging.Ai 3.0 calculator), Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), and subjective general health assessment [36-Item Short Form Survey Instrument (SF-36)].
Show in the study text Report a problemFND-3648225806
04HumanRandomized controlled trialEfficacy outcome
In healthy middle-aged adults, calculated blood biological age stayed unchanged with NMN but increased with placebo, with a significant between-group difference.
In plain wordsIn healthy middle-aged adults, calculated blood biological age stayed unchanged with NMN but increased with placebo, with a significant difference between groups.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
DecreaseBlood biological age at day 60
Study
n = 80
Comparator
placebo
Analysis
Secondary
Outcome group
Aging markers · Aging and longevity
Studied dose
300 mg, 600 mg or 900 mg NMN daily · oral · 60 daysAs given in this study (human).
Source sentences
Summary
The blood biological age increased significantly in the placebo group and stayed unchanged in all NMN-treated groups at day 60, which resulted in a significant difference between the treated groups and placebo (all p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
This randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial included 80 middle-aged healthy adults being randomized for a 60-day clinical trial with once daily oral dosing of placebo, 300 mg, 600 mg, or 900 mg NMN.
Summary · context
The secondary objectives were to assess the safety and tolerability of NMN supplementation, next to the evaluation of clinical efficacy by measuring physical performance (six-minute walking test), blood biological age (Aging.Ai 3.0 calculator), Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), and subjective general health assessment [36-Item Short Form Survey Instrument (SF-36)].
Show in the study text Report a problemFND-3648225810
05HumanRandomized controlled trialEfficacy outcome
In healthy middle-aged adults, HOMA-IR did not differ significantly between NMN and placebo at day 60.
In plain wordsIn healthy middle-aged adults, HOMA-IR did not differ significantly between NMN and placebo at day 60.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
No significant changeHOMA-IR at day 60
Study
n = 80
Comparator
placebo
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
300 mg, 600 mg or 900 mg NMN daily · oral · 60 daysAs given in this study (human).
Source sentences
Summary
The HOMA-IR showed no statistically significant differences for all NMN-treated groups as compared to placebo at day 60.
2 context sentences(design, population, supporting numbers)
Summary · context
This randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial included 80 middle-aged healthy adults being randomized for a 60-day clinical trial with once daily oral dosing of placebo, 300 mg, 600 mg, or 900 mg NMN.
Summary · context
The secondary objectives were to assess the safety and tolerability of NMN supplementation, next to the evaluation of clinical efficacy by measuring physical performance (six-minute walking test), blood biological age (Aging.Ai 3.0 calculator), Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), and subjective general health assessment [36-Item Short Form Survey Instrument (SF-36)].
Show in the study text Report a problemFND-3648225813
06HumanRandomized controlled trialEfficacy outcome
In healthy middle-aged adults, NMN at 600 and 900 mg daily improved SF-36 score change versus placebo at days 30 and 60.
In plain wordsIn healthy middle-aged adults, NMN at 600 and 900 mg daily improved SF-36 health scores versus placebo at days 30 and 60.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
IncreaseSF-36 at days 30 and 60
Study
n = 80
Comparator
placebo
Analysis
Secondary
Outcome group
Quality of life · Whole body
Studied dose
600 mg or 900 mg NMN daily · oral · 60 daysAs given in this study (human).
Source sentences
Summary
The change of SF-36 scores at day 30 and day 60 indicated statistically significantly better health of all three treated groups when compared to the placebo group (p < 0.05), except for the SF-36 score change in the 300 mg group at day 30.
2 context sentences(design, population, supporting numbers)
Summary · context
This randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial included 80 middle-aged healthy adults being randomized for a 60-day clinical trial with once daily oral dosing of placebo, 300 mg, 600 mg, or 900 mg NMN.
Summary · context
The secondary objectives were to assess the safety and tolerability of NMN supplementation, next to the evaluation of clinical efficacy by measuring physical performance (six-minute walking test), blood biological age (Aging.Ai 3.0 calculator), Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), and subjective general health assessment [36-Item Short Form Survey Instrument (SF-36)].
Show in the study text Report a problemFND-3648225818
07HumanRandomized controlled trialEfficacy outcome
In healthy middle-aged adults, NMN did not significantly improve SF-36 score change versus placebo at day 30.
In plain wordsIn healthy middle-aged adults, NMN did not significantly improve SF-36 score change compared with placebo at day 30.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
No significant changeSF-36 at day 30
Study
n: not reported in source
Comparator
placebo
Analysis
Secondary
Outcome group
Quality of life · Whole body
Studied dose
300 mg daily · oral · 60 daysAs given in this study (human).
Source sentences
Summary
The change of SF-36 scores at day 30 and day 60 indicated statistically significantly better health of all three treated groups when compared to the placebo group (p < 0.05), except for the SF-36 score change in the 300 mg group at day 30.
2 context sentences(design, population, supporting numbers)
Summary · context
This randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial included 80 middle-aged healthy adults being randomized for a 60-day clinical trial with once daily oral dosing of placebo, 300 mg, 600 mg, or 900 mg NMN.
Summary · context
The secondary objectives were to assess the safety and tolerability of NMN supplementation, next to the evaluation of clinical efficacy by measuring physical performance (six-minute walking test), blood biological age (Aging.Ai 3.0 calculator), Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), and subjective general health assessment [36-Item Short Form Survey Instrument (SF-36)].
Show in the study text Report a problemFND-3648225816
08HumanRandomized controlled trialEfficacy outcome
In healthy middle-aged adults, NMN improved SF-36 score change versus placebo at day 60.
In plain wordsIn healthy middle-aged adults, NMN improved SF-36 score change compared with placebo at day 60.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
IncreaseSF-36 at day 60
Study
n: not reported in source
Comparator
placebo
Analysis
Secondary
Outcome group
Quality of life · Whole body
Studied dose
300 mg daily · oral · 60 daysAs given in this study (human).
Source sentences
Summary
The change of SF-36 scores at day 30 and day 60 indicated statistically significantly better health of all three treated groups when compared to the placebo group (p < 0.05), except for the SF-36 score change in the 300 mg group at day 30.
2 context sentences(design, population, supporting numbers)
Summary · context
This randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial included 80 middle-aged healthy adults being randomized for a 60-day clinical trial with once daily oral dosing of placebo, 300 mg, 600 mg, or 900 mg NMN.
Summary · context
The secondary objectives were to assess the safety and tolerability of NMN supplementation, next to the evaluation of clinical efficacy by measuring physical performance (six-minute walking test), blood biological age (Aging.Ai 3.0 calculator), Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), and subjective general health assessment [36-Item Short Form Survey Instrument (SF-36)].
Show in the study text Report a problemFND-3648225817

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedNot applicableNCT04823260

To Evaluate the Efficacy and Safety of NMN as an Anti-ageing Supplement in Middle Aged and Older (40-65 Years) Adults

Abinopharm, Incn = 9025 May 2021 to 9 Sept 2021

Aging

Trial page ClinicalTrials.govUpdated 1 Oct 2021

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 1
21 Oct 2026, 12:50 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.